Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Cayman Islands 98-1579063 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

Shareholder Structure and Governance - The Controlling Shareholder owns 71.5% of the total issued and outstanding Ordinary Shares, representing 84.64% of the total voting power, which may not align with the interests of other shareholders [39]. - The dual-class voting structure allows the Controlling Shareholder to exert significant control over corporate actions, which may not be beneficial to other shareholders [43]. - Conflicts of interest may arise due to overlapping business interests of directors and officers with NCH, potentially impacting decision-making [45]. - The company has implemented measures to improve corporate governance, including the appointment of independent Directors and the establishment of an audit committee [56]. Financial Reporting and Internal Controls - The company is in the process of establishing and improving internal controls over financial reporting to enhance accuracy and prevent fraud [55]. - The company is subject to internal control requirements, and failure to maintain effective internal controls may adversely affect its business and the trading price of its Class A Ordinary Shares [57]. Regulatory Environment and Risks - Key operations are based in Hong Kong, but regulatory uncertainty exists due to potential oversight from the Chinese government, which could materially impact operations and share value [58]. - Recent regulatory actions by the Chinese government may limit the company's ability to conduct business and accept foreign investments, potentially leading to a decline in share value [60]. - The SEC has highlighted risks associated with investing in companies with substantial operations in China, including difficulties in enforcing regulatory actions [88]. - The company is not currently required to obtain permissions from PRC authorities for its operations, but future changes in regulations could impose significant restrictions [67]. - The legal system in Hong Kong presents uncertainties that could limit legal protections for the company's operations and contractual rights [69]. Customer and Supplier Dependency - The company relies on one major customer, contributing approximately 71.3%, 91.4%, and 94.5% of total revenues for the years ended December 31, 2023, 2022, and 2021, respectively [102]. - The company’s two principal suppliers accounted for 100%, 93.9%, and 80.1% of total purchases for the years ended December 31, 2024, 2023, and 2022, respectively [108]. - The company does not have long-term agreements with any of its top five customers, making it vulnerable to fluctuations in demand [102]. Market and Competitive Landscape - The apparel supply chain services industry is highly competitive, with many participants leading to pricing pressure and potential loss of customers [122]. - The company may face challenges in attracting new clients who are existing customers of NCH, limiting market share expansion [42]. - The company faces intense competition in a fragmented industry, with competitors having greater resources and access to offshore manufacturing [208]. Economic and Environmental Factors - Political and trade tensions between the U.S. and China may adversely affect the company’s business operations and financial position [96]. - The company faces risks from the Uyghur Forced Labor Prevention Act, which could impact the importation of goods produced in the PRC, particularly from Xinjiang, where 84% of Chinese cotton is sourced [105]. - Global climate change and related regulatory developments could negatively impact the company's operations, particularly in regions experiencing severe weather events [137]. Sustainability and Innovation - The company has received certifications under various sustainable standards, including the Global Recycled Standard 4.0 and the Organic Content Standard 3.0, to enhance its appeal to customers [161]. - The company is committed to reducing environmental impact through recycling, clean processes, and traceable sourcing [150]. - The company has established a recycling project with a top customer to recover boiled wool waste and recycle it into new production materials [159]. - The company has successfully integrated sustainability into its business model, requiring manufacturers to use recycled materials and providing eco-friendly yarn options [164]. Operational Challenges - The company faces risks from labor disruptions at ports and suppliers, which could lead to delays in inventory deliveries and negatively affect sales [117]. - Increasing costs of raw materials and labor could adversely affect profit margins, as the company may not be able to pass on these costs to customers [119]. - Seasonal fluctuations in demand are expected, with sales of finished garment products generally highest from August to December, potentially impacting operating results [116]. Future Growth and Strategic Initiatives - The company plans to pursue acquisitions and joint ventures to diversify revenue sources and enhance market presence, although no specific targets have been identified yet [167][168]. - The company aims to strengthen its market position by enhancing design and development capabilities, focusing on sustainable materials in future product designs [163]. - The company expects continued growth in demand for its apparel services as consumers become more conscious of ethical consumerism and ESG factors [166].

Company Merger and Structure - Conduit Pharmaceuticals completed a merger with Murphy Canyon Acquisition Corp on September 22, 2023, resulting in a name change to Conduit Pharmaceuticals Inc.[163] Financial Performance - The net loss for the three months ended March 31, 2025, was $5.1 million, compared to a net loss of $3.6 million for the same period in 2024[185]. - Operating losses for the three months ended March 31, 2025, were $5.1 million, compared to $3.6 million for the same period in 2024, reflecting a year-over-year increase of approximately 42%[192]. - Total operating costs and expenses for the three months ended March 31, 2025, were $4.0 million, compared to $3.0 million for the same period in 2024[185]. - Net cash used in operating activities for the three months ended March 31, 2025, was $4.3 million, compared to $2.4 million for the same period in 2024, indicating a significant increase in cash outflow[204][205]. - Interest expense for the three months ended March 31, 2025, was $0.2 million, an increase of 48% compared to $0.1 million for the same period in 2024[191]. Research and Development - Research and development expenses increased by $1.2 million, or 923%, to approximately $1.3 million for the three months ended March 31, 2025, compared to $0.1 million for the same period in 2024[186]. - Conduit plans to leverage AI and cybernetics technology through a partnership with SARBORG Limited to enhance drug development efficiency and reduce costs[172][176]. - The company has a pending international patent application and two pending national patent applications related to its proprietary solid-form technology[180]. - AstraZeneca has licensed certain intellectual property rights to Conduit for further development of HK-4 Glucokinase activators and myeloperoxidase inhibitors[169]. - Conduit aims to pursue additional partnerships for licensing further assets that are currently deprioritized, focusing on developing clinical assets for widespread disorders[177]. Financial Needs and Projections - Cash required for working capital over the next 12 months is estimated at $12.7 million, including $1.3 million for research and development and $7.2 million for general and administrative costs[200]. - As of March 31, 2025, the company had raised $11.9 million (net of fees) out of the $23.9 million available through the Sales agreement, with an expectation to raise an additional $11.6 million over the next 12 months[201]. - The company anticipates significant cash needs for ongoing research and development and business operations, which may require additional financing through equity or debt[193]. Going Concern and Company Classification - The company has substantial doubt regarding its ability to continue as a going concern for at least 12 months from the filing date of the Quarterly Report[195]. - Conduit is classified as a smaller reporting company, with non-affiliate common stock valued at less than $250.0 million as of the last business day of the second fiscal quarter[222]. - Conduit's annual revenue is below $100.0 million for the most recently completed fiscal year, with non-affiliate common stock valued at less than $700.0 million[222]. - The company may continue to utilize scaled disclosures available to smaller reporting companies[222]. - There is no requirement for the company to disclose quantitative and qualitative market risk due to its smaller reporting company status[223]. Lease Obligations - The company has a laboratory space lease with annual rent payments of $0.1 million for the years ending December 31, 2025, and December 31, 2026[210].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41245 CONDUIT PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) | Delaware | 87-3272543 | | --- | --- ...

Financial Performance - Klotho Neurosciences, Inc. reported no revenue for the three months ended March 31, 2025 and 2024 [112]. - The net loss for the three months ended March 31, 2025 was $2,233,982, compared to a net loss of $672,044 for the same period in 2024, indicating a significant increase in losses [114]. Operating Expenses - Operating expenses increased to $1,586,968 for the three months ended March 31, 2025, up from $672,045 in the same period in 2024, representing an increase of approximately 136% [113]. Cash Flow - Net cash used in operating activities rose to $1,553,747 for the three months ended March 31, 2025, compared to $21,976 for the same period in 2024, an increase of approximately 6,000% [116]. - Cash at the end of the year was $565,869 as of March 31, 2025, compared to $32,336 at the end of the previous year [115]. - Net cash provided by financing activities was $2,055,875 for the three months ended March 31, 2025, an increase of approximately 1,070% compared to $175,000 in the same period in 2024 [118]. Accumulated Deficit - The company has an accumulated deficit of approximately $12.8 million as of March 31, 2025 [120]. Business Operations - The company expects to continue incurring significant professional costs to remain publicly traded and has incurred significant transaction costs related to the business combination [119]. - Klotho Neurosciences, Inc. is classified as an "emerging growth company" and intends to take advantage of certain exemptions from reporting requirements [122]. - The company has no off-balance sheet arrangements as of March 31, 2025 [121].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42267 VINE HILL CAPITAL INVESTMENT CORP. (Exact name of registrant as specified in its charter) | Cayman Islands | 98-1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42267 VINE HILL CAPITAL INVESTMENT CORP. (Exact name of registrant as specified in its charter) | Cayman Islands | 98-1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-41509 Nxu, Inc. (Exact name of registrant as specified in its charter) Delaware 92-2819012 (State or other jurisdiction of incorporation or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-41509 Nxu, Inc. (Exact name of registrant as specified in its charter) Delaware 92-2819012 (State or other jurisdiction of incorporation or o ...